HUTCHMED (China) (HMDCF) Notes Payables (2015 - 2025)

HUTCHMED (China) (HMDCF) reported Notes Payables of $25.0 million for Q4 2025, down 2.47% quarter-over-quarter from $25.6 million in Q2 2025.

HUTCHMED (China) (HMDCF) Notes Payables (2015 - 2025) Analysis & Trends

HUTCHMED (China) (HMDCF) has 5 years of Notes Payables data on file, last reported at $25.0 million in Q4 2025.

Notes Payables for Q4 2025 came in at $25.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $25.0 million (changed N/A YoY), and the FY2025 annual result was $25.0 million, changed N/A from the prior year.
Notes Payables declined to $25.0 million in Q4 2025 per HMDCF's latest filing, from $25.6 million in the prior quarter.
Over five years, Notes Payables peaked at $26.5 million in Q2 2024 and troughed at $25.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	HUTCHMED (China)	-	-	-

Download Data